Literature DB >> 2036533

Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography.

R Hunter1, D J Wyper, J Patterson, M T Hansen, G M Goodwin.   

Abstract

The effects of physostigmine on patterns of rCBF in patients with pre-senile Alzheimer's disease were studied using 99mTc-labelled HMPAO SPECT. Regional CBF increased in the left cortex relative to right, with the most significant effect in left frontal and higher frontal regions. Measures of regional brain function, such as SPECT, are an important complement to psychological test batteries in understanding the effects in brain of putative antidementia drugs. SPECT brain imaging could extend our understanding of the action of psychotropic drugs in other major psychiatric illnesses.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2036533     DOI： 10.1192/bjp.158.3.351

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  10 in total

Review 1.  Functional imaging of the brain in the evaluation of drug response and its application to the study of aging.

Authors:  C A Bryant; S H Jackson
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 3.923

2.  Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.

Authors:  E Stefanova; A Wall; O Almkvist; A Nilsson; A Forsberg; B Långström; A Nordberg
Journal:  J Neural Transm (Vienna)       Date:  2005-07-29       Impact factor: 3.575

3.  Cholinergic treatment of an amnestic man with a basal forebrain lesion: theoretical implications.

Authors:  A Chatterjee; M K Morris; D Bowers; D J Williamson; L Doty; K M Heilman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-12       Impact factor: 10.154

Review 4.  Neuroimaging in Alzheimer's disease: relevance for treatment.

Authors:  C H van Dyck
Journal:  Curr Psychiatry Rep       Date:  2001-02       Impact factor: 5.285

Review 5.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  A neurochemical approach for studying response to acetylcholine in Alzheimer's disease.

Authors:  J T Alder; I P Chessell; D M Bowen
Journal:  Neurochem Res       Date:  1995-07       Impact factor: 3.996

7.  A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease.

Authors:  J T O'Brien; S Eagger; G M Syed; B J Sahakian; R Levy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

8.  Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.

Authors:  T Sunderland; G Esposito; S E Molchan; R Coppola; D W Jones; J Gorey; J T Little; M Bahro; D R Weinberger
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

9.  Hypofrontality revisited: a high resolution single photon emission computed tomography study in schizophrenia.

Authors:  K P Ebmeier; S M Lawrie; D H Blackwood; E C Johnstone; G M Goodwin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-04       Impact factor: 10.154

10.  Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease.

Authors:  K P Ebmeier; R Hunter; S M Curran; N J Dougal; C L Murray; D J Wyper; J Patterson; M T Hanson; K Siegfried; G M Goodwin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.